To test whether EPO influences survival and may reduce cisplatin-induced apoptosis in NSCLC cells, H838 and H838-HA-hEPOR cells were treated with 5 mg/l of the chemotherapeutic agent cisplatin in combination with 10 U/ml EPO beta or were left untreated for three days. This evidence concerns the gene EPO and non-small cell lung carcinoma.